ATE488581T1 - Faktor vii oder faktor viia polypeptidvarianten - Google Patents

Faktor vii oder faktor viia polypeptidvarianten

Info

Publication number
ATE488581T1
ATE488581T1 AT03717173T AT03717173T ATE488581T1 AT E488581 T1 ATE488581 T1 AT E488581T1 AT 03717173 T AT03717173 T AT 03717173T AT 03717173 T AT03717173 T AT 03717173T AT E488581 T1 ATE488581 T1 AT E488581T1
Authority
AT
Austria
Prior art keywords
factor
polypeptide variants
variants
viia polypeptide
vii
Prior art date
Application number
AT03717173T
Other languages
English (en)
Inventor
Jesper Haaning
Kim Andersen
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Application granted granted Critical
Publication of ATE488581T1 publication Critical patent/ATE488581T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AT03717173T 2002-04-30 2003-04-29 Faktor vii oder faktor viia polypeptidvarianten ATE488581T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37667902P 2002-04-30 2002-04-30
PCT/DK2003/000276 WO2003093465A1 (en) 2002-04-30 2003-04-29 FACTOR VII OR VIIa POLYPEPTIDE VARIANTS

Publications (1)

Publication Number Publication Date
ATE488581T1 true ATE488581T1 (de) 2010-12-15

Family

ID=29401388

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03717173T ATE488581T1 (de) 2002-04-30 2003-04-29 Faktor vii oder faktor viia polypeptidvarianten

Country Status (22)

Country Link
US (6) US7700733B2 (de)
EP (1) EP1499719B1 (de)
JP (2) JP2005523723A (de)
KR (1) KR101121593B1 (de)
CN (2) CN1665925A (de)
AT (1) ATE488581T1 (de)
AU (2) AU2003221469A1 (de)
BR (1) BR0309576A (de)
CA (1) CA2483478A1 (de)
CY (1) CY1111626T1 (de)
DE (1) DE60334983D1 (de)
DK (1) DK1499719T3 (de)
ES (1) ES2355713T3 (de)
IL (1) IL164764A (de)
MX (1) MXPA04010781A (de)
NZ (1) NZ536340A (de)
PL (1) PL373728A1 (de)
PT (1) PT1499719E (de)
RU (1) RU2004134726A (de)
SI (1) SI1499719T1 (de)
WO (1) WO2003093465A1 (de)
ZA (1) ZA200409475B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
PL206148B1 (pl) 2000-02-11 2010-07-30 Bayer HealthCare LLCBayer HealthCare LLC Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
RU2004134726A (ru) * 2002-04-30 2005-06-10 Максиджен Холдингз Лтд. (Ky) Варианты полипептида фактора vii или viia
CA2840692A1 (en) * 2002-09-30 2004-04-08 Bayer Healthcare Llc Fvii or fviia variants having increased clotting activity
CA2519873C (en) 2003-03-20 2012-12-18 Maxygen Holdings Ltd. Fvii or fviia variants
ATE458057T1 (de) * 2003-06-19 2010-03-15 Bayer Healthcare Llc Varianten der faktor-vii- oder -viia-gla-domäne
ES2381110T3 (es) 2003-09-09 2012-05-23 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación
CN1890257A (zh) 2003-12-01 2007-01-03 诺和诺德医疗保健公司 液体因子ⅶ组合物的病毒过滤
KR20140093711A (ko) 2003-12-19 2014-07-28 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
MX2007001294A (es) 2004-08-17 2008-03-04 Zlb Behring Gmbh Polipeptidos modificados que dependen de vitamina k.
MX2007002903A (es) * 2004-09-10 2007-07-11 Pharmaorigin Aps Metodos para el tratamiento de hemoptisis o hemorragias traqueales, bronquiales o alveolares, locales.
EP2360171A1 (de) 2004-12-23 2011-08-24 Novo Nordisk Health Care AG Reduktion des Gehaltes an kontaminierenden Proteinen in Zusammensetzungen, die Vitamin K-abhängige Proteine von Interesse umfassen
WO2006114105A2 (en) * 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
EP2360170A3 (de) 2005-06-17 2012-03-28 Novo Nordisk Health Care AG Selektive Reduktion und Derivatisierung von Proteinen die mindestens ein nicht-natives Cystein enthalten
US7696318B2 (en) 2005-07-13 2010-04-13 Novo Nordisk Health Care Ag Host cell protein knock-out cells for production of therapeutic proteins
EP1924689B1 (de) 2005-09-01 2014-08-13 Novo Nordisk Health Care AG Reinigung von faktor-vii-polypeptiden mittels hydrophober interaktionschromatografie
JP5690047B2 (ja) 2005-09-14 2015-03-25 ノボ ノルディスク ヘルス ケア アーゲー ヒト凝固第ｖｉｉ因子ポリペプチド
EP2031968B1 (de) * 2006-04-21 2017-11-22 Wake Forest University Health Sciences Strukturell modifizierte azelluläre gewebe-engineering-gerüste und herstellungsverfahren
US20100056428A1 (en) 2006-09-01 2010-03-04 Novo Nordisk Health Care Ag Modified proteins
JP2010513462A (ja) * 2006-12-20 2010-04-30 バイエル・ヘルスケア・エルエルシー 第ＶＩＩおよび第ＶＩＩａ因子組成物
BRPI0810172A2 (pt) * 2007-04-13 2014-10-14 Catalyst Biosciences Inc Polipeptídeos de fator vii modificado e seus usos
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
US8354377B2 (en) 2008-01-18 2013-01-15 Novo Nordisk Health Care Ag Use of factor VIIa or factor VIIa equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ICH) in a selected subpopulation of ICH patients
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
CN102112157B (zh) 2008-08-06 2013-05-29 诺沃-诺迪斯克保健股份有限公司 具有延长的体内效能的缀合蛋白
EP2389389B1 (de) 2009-01-22 2015-04-15 Novo Nordisk Health Care AG Stabile Wachstumshormonverbindungen
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
WO2011018515A1 (en) 2009-08-14 2011-02-17 Novo Nordisk Health Care Ag Method of purifying pegylated proteins
SI2525834T1 (sl) 2010-01-22 2019-10-30 Novo Nordisk Healthcare Ag Rastni hormoni s podaljšano in vivo učinkovitostjo
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
CN102834104A (zh) * 2010-02-22 2012-12-19 优势医疗公司 治疗脑的出血性病状的方法和组合物
EP2694133B1 (de) 2011-04-05 2018-05-23 Edge Therapeutics, Inc. Intraventrikuläres arzneimittelabgabesystem zur verbesserung der ergebnisse nach einer den zerebralen blutfluss beeinflussenden hirnverletzung
PT2717898T (pt) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Compostos pró-coagulantes e processos para a sua utilização
EP2554161A1 (de) * 2011-08-02 2013-02-06 LFB Biotechnologies Pharmazeutische Zusammensetzung enthaltend Faktor VII in Mizellen verkapselt
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
CN119192402A (zh) 2012-02-15 2024-12-27 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
WO2013177584A2 (en) * 2012-05-25 2013-11-28 The Children's Hospital Of Philadelphia FVIIa VARIANTS EXHIBITING ALTERED INTERACTION WITH ENDOTHELIAL PROTEIN C RECEPTOR (EPCR) AND METHODS OF USE THEREOF FOR MODULATING HEMOSTASIS
WO2014105784A1 (en) * 2012-12-24 2014-07-03 Bayer Healthcare Llc Short-acting factor vii polypeptides
TW201442721A (zh) 2013-01-23 2014-11-16 Daiichi Sankyo Co Ltd 糖鏈修飾心房利尿鈉肽
EP2981282B1 (de) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Wachstumshormonverbindungsformulierung
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
CA2994547A1 (en) 2015-08-03 2017-02-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
US12161696B2 (en) 2016-12-02 2024-12-10 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法
EP3833381B1 (de) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modifizierte faktor-vii-polypeptide zur subkutanen verabreichung

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5180583A (en) * 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
US5258288A (en) * 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
DK323587D0 (da) 1987-06-25 1987-06-25 Novo Industri As Protein
PT87688B (pt) 1987-06-12 1992-09-30 Hoechst Japan Processo para a preparacao de proteina hibrida c
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
JPH0246296A (ja) 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
JP2928287B2 (ja) * 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
ATE181732T1 (de) 1989-04-19 1999-07-15 Novo Nordisk As Aktive karbonate von polyalkylenoxyden zur modifizierung von polypeptiden
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
FI923347A0 (fi) 1990-01-26 1992-07-23 Immuno Ag Blodfaktorer producerade med rekombinant-dna-teknik och foerfarande foer expression av naemnda blodfaktorer samt i naemnda foerfarande anvaenda rekombinanta kokoppvirus.
JP3330932B2 (ja) * 1990-01-29 2002-10-07 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 抗凝固剤タンパク質
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5531916A (en) 1990-10-03 1996-07-02 E. I. Du Pont De Nemours And Company Hydrofluorocarbon cleaning compositions
JP4236698B2 (ja) * 1990-11-26 2009-03-11 ジェネティックス インスティチュート，リミテッド ライアビリティ カンパニー 宿主細胞でのｐａｃｅの発現およびその使用法
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
ATE273393T1 (de) 1991-02-28 2004-08-15 Zymogenetics Inc Modifizierter faktor-vii
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
GB9122048D0 (en) * 1991-10-17 1991-11-27 Interox Chemicals Ltd Compositions and uses thereof
JPH0720127A (ja) * 1993-05-07 1995-01-24 Eisai Co Ltd 各種ｐｉｖｋａの測定方法および測定試薬
DE69429429T2 (de) 1993-05-21 2002-05-16 Novo Nordisk A/S, Bagsvaerd MODIFIZIERTER FAKTOR VII zur Hemmung der vaskulären Restenosis und Thrombozytenablagerung
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
US5837843A (en) * 1996-11-08 1998-11-17 Oklahoma Medical Research Foundation Modified protein C
AU730133B2 (en) * 1996-11-08 2001-02-22 Oklahoma Medical Research Foundation Modified protein C and methods of use thereof
AU5773798A (en) 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
CA2279986A1 (en) 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
IL133974A0 (en) 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
AU8101698A (en) 1997-07-18 1999-02-10 Novo Nordisk A/S Use of fviia or fviiai for the treatment of adverse conditions related to the fviia mediated intracellular signalling pathway
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
JP2002531067A (ja) 1998-10-30 2002-09-24 ノボザイムス アクティーゼルスカブ 低下したアレルゲン性を有するグリコシル化タンパク質
ATE263778T1 (de) 1998-10-30 2004-04-15 Novozymes As Niedrigallergene proteinvarianten
ATE408020T1 (de) 1998-11-06 2008-09-15 Novo Nordisk Healthcare Ag Verfahren zur herstellung von faktor vii
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
PL206148B1 (pl) * 2000-02-11 2010-07-30 Bayer HealthCare LLCBayer HealthCare LLC Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
US7220837B1 (en) * 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
WO2001083725A1 (en) 2000-05-03 2001-11-08 Novo Nordisk A/S Human coagulation factor vii variants
US6423826B1 (en) * 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
JP4361728B2 (ja) 2000-09-13 2009-11-11 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固因子ｖｉｉ変異型
CN100475959C (zh) * 2000-09-13 2009-04-08 诺沃挪第克健康护理股份公司 人凝血因子vii变体
IL154879A0 (en) 2000-10-02 2003-10-31 Novo Nordisk As Factor vii glycoforms
US7173000B2 (en) 2000-11-09 2007-02-06 The Scripps Research Institute Modified factor VIIa
AU2002249096B2 (en) 2001-03-22 2007-06-28 Novo Nordisk Health Care Ag Coagulation factor VII derivatives
US7052868B2 (en) * 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
PL368619A1 (en) 2001-09-27 2005-04-04 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
AU2002336919A1 (en) 2001-11-02 2003-05-12 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
US7024693B2 (en) * 2001-11-13 2006-04-04 Sun Microsystems, Inc. Filter-based attribute value access control
CN1607958A (zh) 2001-12-21 2005-04-20 诺和诺德医疗保健公司 因子ⅶ多肽的液体组合物
RU2004134726A (ru) 2002-04-30 2005-06-10 Максиджен Холдингз Лтд. (Ky) Варианты полипептида фактора vii или viia
CA2840692A1 (en) 2002-09-30 2004-04-08 Bayer Healthcare Llc Fvii or fviia variants having increased clotting activity
CA2519873C (en) 2003-03-20 2012-12-18 Maxygen Holdings Ltd. Fvii or fviia variants
ATE458057T1 (de) * 2003-06-19 2010-03-15 Bayer Healthcare Llc Varianten der faktor-vii- oder -viia-gla-domäne
US7185570B2 (en) 2005-01-18 2007-03-06 Chih-Ching Hsieh Spanner with enhancing structure for positioning electronic devices installed therein
US20060252669A1 (en) 2005-05-06 2006-11-09 Marija Heibel Fabric care composition comprising polymer encapsulated fabric or skin beneficiating ingredient

Also Published As

Publication number Publication date
US20060270002A1 (en) 2006-11-30
US20100260741A1 (en) 2010-10-14
ZA200409475B (en) 2005-09-28
AU2003221469A1 (en) 2003-11-17
US9353365B2 (en) 2016-05-31
BR0309576A (pt) 2005-02-09
KR101121593B1 (ko) 2012-04-12
US7700733B2 (en) 2010-04-20
CY1111626T1 (el) 2015-10-07
KR20040106424A (ko) 2004-12-17
DE60334983D1 (de) 2010-12-30
US20060111282A1 (en) 2006-05-25
EP1499719B1 (de) 2010-11-17
PL373728A1 (en) 2005-09-05
MXPA04010781A (es) 2005-03-07
DK1499719T3 (da) 2011-02-28
CA2483478A1 (en) 2003-11-13
NZ536340A (en) 2006-09-29
PT1499719E (pt) 2011-02-09
SI1499719T1 (sl) 2011-03-31
RU2004134726A (ru) 2005-06-10
US20060276377A1 (en) 2006-12-07
US20060270001A1 (en) 2006-11-30
AU2008261165A1 (en) 2009-01-15
ES2355713T3 (es) 2011-03-30
JP2005523723A (ja) 2005-08-11
IL164764A (en) 2013-07-31
US20060270000A1 (en) 2006-11-30
JP2010213706A (ja) 2010-09-30
CN1665925A (zh) 2005-09-07
CN101942019A (zh) 2011-01-12
EP1499719A1 (de) 2005-01-26
WO2003093465A1 (en) 2003-11-13
IL164764A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
ATE488581T1 (de) Faktor vii oder faktor viia polypeptidvarianten
ATE458057T1 (de) Varianten der faktor-vii- oder -viia-gla-domäne
DK1257295T3 (da) Faktor VII eller VIIA-lignende molekyler
ITMI20010562A1 (it) Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
ATE437221T1 (de) Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
DE60204225D1 (de) Verwendung von biologisch aktivem glas zum schneiden von biologisch aktivem glas
PL370536A1 (en) Compositions for treatment of common cold
PT1107996E (pt) Anticorpos humanos anti-factor ix/ixa
IS6072A (is) Æðasamloðunar sameindir og mótun á starfsemi þeirra
DE50212280D1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
DE69615185D1 (de) Faktor ix bindende peptide abgeleitet von faktor vii und ihre verwendung als inhibitoren der blutgerinnung
HUP0400458A2 (hu) Kobalaminkötő fehérjéket expresszáló transzgenikus növények
BRPI0412477A (pt) aperfeiçoados polipeptìdeos de interferon-beta-1b recombinantes humanos
DE60222669D1 (de) Asthma-assoziiertes gen
ATE554393T1 (de) Diagnostika und therapeutika für mit adiponectin receptor 2 (adipor2) assoziierten erkrankungen
FR2830865B1 (fr) Leurres peptidiques pour la preparation de medicaments destines a la prevention ou au traitement des pathologies auto-immunes, ou des troubles lies a l'apparition d'anticorps diriges contre des proteines exogenes
WO2004058811A3 (en) Crystal structures of yhhf polypeptides
DE60129133D1 (de) Verwendung von Clarithromycin zur Herstellung eines Medikaments für die Behandlung von Arthrosis deformans

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1499719

Country of ref document: EP